肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
Erratum to "CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic leukemia using a Coccidioides immitis-derived group II intron pl
Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models.
降低化疗后的复发率仍是提高肿瘤治疗疗效的一大挑战。
Donor-derived CD19-targeted CAR-NK cells induce complete remission in a child with relapsed B-ALL after failure of blinatumomab and autologous CD19-ta
复发仍是儿童 B 细胞急性淋巴细胞白血病（B-ALL）治疗失败和死亡的主要原因。
CircRNA-based CD19-targeted CAR-NK therapy for B-cell acute lymphoblastic Leukemia using a Coccidioides immitis-derived group II intron platform.
这些结果支持基于circRNA的CAR-NK疗法作为提高癌症免疫治疗安全性和有效性的一种有效方法的潜力。
Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer.
T细胞导向的免疫疗法已改变了血液系统恶性肿瘤的治疗，但持久获益仍受限于复发、持续性差、免疫重建不完全和感染。
Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia.
这些数据表明 aCD19 CAR NK 细胞作为 BCP-ALL 联合治疗组成部分的潜力，应在临床试验中进一步评估。
Tumor-priming CD8(+) natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma.
TPNC 是一种通过肿瘤驱动的致敏产生的新型细胞毒性淋巴细胞产品。
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies.
我们的研究提供了一种可靠的策略，可从 hPSCs 大规模生成具有强效抗肿瘤作用的抗自相残杀 CD7 CAR-iNK 细胞，为治疗 T 细胞恶性肿瘤提供了一种有前景的细胞产品。
Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial.
我们的临床前和临床数据表明，CD33 CAR-NK 细胞对 R/R 急性髓系白血病患者具有初步疗效和安全性。
iPSC-derived NK cells with site-specific integration of CAR19 and IL24 at the multi-copy rDNA locus enhanced antitumor activity and proliferation.
利用诱导多能干细胞（iPSC）制备嵌合抗原受体修饰的自然杀伤（CAR-NK）细胞，已成为生产现货型通用免疫疗法的范式之一。
MEMBER ACCOUNT
登录成功会直接打开下一页。
